About BioGenomics
BioGenomics is a Healthcare company based in Thane (India) founded in 2002 by Archana Krishnan and Sanjay Sonar. Recombinant DNA-based biosimilars, proteins, and enzymes are developed. BioGenomics has raised $69.54 million across 5 funding rounds from investors including Oman Investment Authority and Eagle Asia Holding. The company has 193 employees. Its chief executive, as recorded, is Sanjay Sonar. Its Indian entity Biogenomics Limited reported revenue of ₹13.42 Cr. BioGenomics offers products and services including Biopharmaceuticals and Recombinant Proteins. Its focus areas include Life Sciences, Diabetes, Drugs and Oncology.
Company details
BioGenomics was founded in 2002 in Thane, India, within the biotechnology sector. Recombinant DNA technology is utilized for biosimilars development, alongside recombinant proteins and enzymes. A platform for biosimilars is provided, including cell-culture reagents and enzymes that serve as replacements for animal-derived components. This enables production processes to be conducted without animal origins. Operations focus on these offerings to support biotech applications.
- Headquarters Thane, India
- Employees 193
- Founders Archana Krishnan, Sanjay Sonar
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biogenomics.co.in
- Social LinkedIn
- Legal Name Biogenomics Limited
- Date of Incorporation 24 Apr, 2002
- Jurisdiction Puducherry, India
- Annual Revenue₹13.42 Cr
FY 2024
- Net Loss-₹24.00 Cr
FY 2024 · -179% margin
- EBITDA-₹26.37 Cr
FY 2024 · -197% margin
- Total Equity Funding$69.54M (USD)
in 5 rounds
- Latest Funding Round$21.35M (USD), Series B
May 2024
- InvestorsOman Investment Authority
& 1 more
- Employee Count193
Associated legal entities of BioGenomics
BioGenomics operates through Biogenomics Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biogenomics Limited CIN U24234PY2002PLC009158 | Active | 24 Apr 2002 | Puducherry, Puducherry | ₹13.4 Cr | 193 | 11 | View details |
Products & Services of BioGenomics
BioGenomics offers a comprehensive portfolio of products and services, including Biopharmaceuticals and Recombinant Proteins.
Develops drugs targeting diabetes and cancer treatments effectively.
Produces proteins for medical applications and research purposes.
Funding Insights of BioGenomics
BioGenomics has successfully raised a total of $69.54M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $21.35 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.54M
- Total Rounds 5
- Last Round Series B — $21.35M
- First Round $24.62M
(Jan 2022)
- Investors Count 2
All 5 funding rounds of BioGenomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $21.35M | Series B | – | Eagle Asia Holding | – |
| Jul 2022 | Seed | – | Oman Investment Authority | – | |
| Jul 2022 | Series B | – | Oman Investment Authority | – | |
| Jan 2022 | $24.62M | Seed | – | Eagle Asia Holding | – |
| Jan 2022 | $23.56M | Series B | – | Eagle Asia Holding | – |
2 investors in total: 2 institutional.
Investors in BioGenomics
BioGenomics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Oman Investment Authority and Eagle Asia Holding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
National investments are managed by the Oman Investment Authority. | oia.gov.om | Muscat, Oman | ||
Investor details for BioGenomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Biogenomics Limited (BioGenomics)
Biogenomics Limited is the primary company behind BioGenomics. The board of Biogenomics Limited currently have 9 directors; the longest-serving is Archana Rajesh Krishnan, appointed in 2006. 24 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Archana Rajesh Krishnan DIN 00208511 | Whole-time director | 03 Feb 2006 | 20 yrs 9 mo | Biogenomics Limited |
| Namit Rustagi DIN 09493933 | Director | 28 Mar 2022 | 4 yrs 7 mo | Biogenomics Limited |
| Ammar Abdullah Hamad Al Ali DIN 09538218 | Director | 28 Mar 2022 | 4 yrs 7 mo | Biogenomics Limited |
| Ali Abdullah Ali Al Aamri DIN 09608439 | Nominee Director | 31 May 2022 | 4 yrs 5 mo | Biogenomics Limited |
| Mohammed Hamdan Saif Al Rubaie DIN 09615093 | Nominee Director | 31 May 2022 | 4 yrs 5 mo | Biogenomics Limited |
| Pushkar Jauhari DIN 06391650 | Nominee Director | 19 Jun 2022 | 4 yrs 4 mo | Biogenomics Limited |
| Rajesh Shashikant Dalal DIN 03504969 | Director | 08 Dec 2023 | 2 yrs 11 mo | Biogenomics Limited |
| Imran Jamiluddin Shaikh DIN 10723912 | Nominee Director | 20 Aug 2024 | 2 yrs 2 mo | Biogenomics Limited |
| Rajiv Malik DIN 00334785 | Additional Director | 01 Jul 2025 | 1 yr 4 mo | Biogenomics Limited |
People of BioGenomics
21 people are tracked at BioGenomics (10 in leadership, 11 in team); the tracked headcount is 193.
| Name | Role | Group |
|---|---|---|
| Co-Founder & Director | Leadership | |
| Co-Founder & Owner & President & CEO | Leadership | |
Rekha Desai | Head-human Resources | Leadership |
Moushmi Mehendale | Head Of HR | Leadership |
Abhishek D. | CFO | Leadership |
Dr. Nitin Joshi | Medical Director-clinical Research | Leadership |
Sudhir Joshi | Head Business Development | Leadership |
Dr. Archana Krishnan | Director | Leadership |
Pradeep Pandit | General Manager (plant) | Leadership |
Sunil Revankar | Head Projects & Engineering- DGM | Leadership |
Hemant Chaudhari | Manager | Team |
Dr Rahul Jangle | Lead Formulation Development Biologics | Team |
Akshay Mahale | Sr. Product Executive | Team |
Karuna Ketan Bhattacharyya | Sales Manager | Team |
Dharmendra Singh Chouhan | Senior Manager | Team |
Dattatray Chavan | Assistant Manager | Team |
Prakash Prabu | Operations Maintenance | Team |
Aruldeivan Deivan | Quality Control Executive | Team |
Priyadarshenee Ravi | Junior Executive | Team |
Syed Ibrahim | Engineering Manager | Team |
1 more people are available in the full profile.
Complete people profiles for BioGenomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of BioGenomics
Figures of Biogenomics Limited, the primary company behind BioGenomics, for FY 2024. Revenue was ₹13.42 Cr. Net loss was -₹24.00 Cr (-179% margin). EBITDA was -₹26.37 Cr (-197% margin).
- ₹13.42 CrRevenue · FY 2024
- -₹24.00 CrNet loss · -179% margin
- -₹26.37 CrEBITDA · -197% margin
- ₹384 CrPaid-up capital
- 193Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Biogenomics Limited are on its company page.
Detailed financial statements for BioGenomics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BioGenomics
3 dated milestones of BioGenomics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded BioGenomics is founded.
- Funding First funding round of $24.6M.
- Funding Latest funding round, Series B, of $21.4M.
Web traffic of BioGenomics
Websites that share an audience with BioGenomics (biogenomics.co.in).
Websites whose visitors overlap most with BioGenomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| epigeneres.com | 100% | 1.7K | #9,769,196 | View details | |
| geneombiotechnologies.com | 76% | View details | |||
| genexindia.net | 72% | 4.3K | #4,385,725 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biogenomics
Complete news archive for BioGenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioGenomics
BioGenomics was founded in 2002 and raised its 1st funding round 20 years after it was founded.
BioGenomics is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
Sanjay Sonar is the CEO of BioGenomics, as recorded in our data. They have also founded this company.
BioGenomics is a funded company, having raised a total of $69.54M across 5 funding rounds to date. The company's 1st funding round was a Seed of $24.62M, raised on Jan 2022.
BioGenomics has 193 employees.
The primary company behind BioGenomics, Biogenomics Limited, reported revenue of ₹13.42 Cr for FY 2024.
BioGenomics was founded in 2002 in Thane, India, within the biotechnology sector. Recombinant DNA technology is utilized for biosimilars development, alongside recombinant proteins and enzymes. A platform for biosimilars is provided, including cell-culture reagents and enzymes that serve as replacements for animal-derived components. This enables production processes to be conducted without animal origins. Operations focus on these offerings to support biotech applications.
BioGenomics offers Biopharmaceuticals and Recombinant Proteins.
BioGenomics has 2 investors. Key investors include Oman Investment Authority, and Eagle Asia Holding.
BioGenomics operates through Biogenomics Limited.
The legal entities of BioGenomics currently have 11 directors, including Pushkar Jauhari, Rajesh Shashikant Dalal, Rajiv Malik and others.